» Authors » Bachra Choufi

Bachra Choufi

Explore the profile of Bachra Choufi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 412
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson-Ansah H, Maneglier B, Huguet F, Legros L, Escoffre-Barbe M, Gardembas M, et al.
Pharmaceutics . 2022 Aug; 14(8). PMID: 36015302
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug’s efficacy or tolerance....
2.
Vercellino L, Cottereau A, Casasnovas O, Tilly H, Feugier P, Chartier L, et al.
Blood . 2020 Jan; 135(16):1396-1405. PMID: 31978225
Early identification of ultra-risk diffuse large B-cell lymphoma (DLBCL) patients is needed to aid stratification to innovative treatment. Previous studies suggested high baseline total metabolic tumor volume (TMTV) negatively impacts...
3.
Choufi B, Alsuliman T
Ther Adv Hematol . 2019 Oct; 10:2040620719879587. PMID: 31632621
Background: Along with continuing changes in therapeutic modalities, indications of autologous hematopoietic stem-cell transplantation (ASCT) have been emerging and changing considerably, especially in the era of targeted therapy and small...
4.
Choufi B, Chalabi N, Le Corre L, Delort L, Satih S, Bignon Y, et al.
Cancer Genomics Proteomics . 2019 Aug; 3(2):113-118. PMID: 31394689
Hematopoietic stem cell (HSC) allograft can be performed with cells of peripheral or medullar origin. Currently, it is the best therapy for certain malignant diseases. The curative power of allografts...
5.
Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, et al.
Am J Hematol . 2018 Oct; 94(1):E24-E27. PMID: 30358899
No abstract available.
6.
Alsuliman T, Belghoul M, Choufi B
Case Rep Hematol . 2018 Sep; 2018:5761627. PMID: 30186643
Nowadays, mantle cell lymphoma is considered to have one of the worst prognostic profiles among lymphoid malignancies. Mantle cell lymphoma rarely affects the central nervous system (CNS) as it represents...
7.
Alsuliman T, Lassoued K, Belghoul M, Debbache K, Choufi B
Dermatol Ther (Heidelb) . 2017 Dec; 8(1):165-169. PMID: 29196889
Introduction: Pentostatin (2'-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) are adenosine analogues widely used to treat lymphoid malignancies, mainly hairy cell leukemia (HCL). Oral or parenteral adenosine analogues have been also used as...
8.
Thieblemont C, Tilly H, Gomes Da Silva M, Casasnovas R, Fruchart C, Morschhauser F, et al.
J Clin Oncol . 2017 Apr; 35(22):2473-2481. PMID: 28426350
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity...
9.
Peyrade F, Bologna S, Delwail V, Emile J, Pascal L, Ferme C, et al.
Lancet Haematol . 2017 Jan; 4(1):e46-e55. PMID: 28041583
Background: In 2011 we reported a rituximab plus miniCHOP (reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone) combination for patients older than 80 years with diffuse large B-cell lymphoma (DLBCL). The 2-year...
10.
Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, et al.
Oncotarget . 2016 Jul; 7(51):85573-85583. PMID: 27458168
Peripheral T-cell lymphoma (PTCL) is a group of diseases with poor outcome and few therapeutic options. We aimed to assess the efficacy of bendamustine in real life cohort of patients.Between...